AR092385A1 - FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA - Google Patents

FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA

Info

Publication number
AR092385A1
AR092385A1 ARP130103082A ARP130103082A AR092385A1 AR 092385 A1 AR092385 A1 AR 092385A1 AR P130103082 A ARP130103082 A AR P130103082A AR P130103082 A ARP130103082 A AR P130103082A AR 092385 A1 AR092385 A1 AR 092385A1
Authority
AR
Argentina
Prior art keywords
hmg
irbesartan
formulation
pharmaceutical capsule
independent
Prior art date
Application number
ARP130103082A
Other languages
English (en)
Spanish (es)
Inventor
Il Kim Yong
Jin Kwon Yoeng
Hyungmin Park Caleb
Yeop Lee Seung
Hyun Park Jae
Soo Woo Jong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092385(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of AR092385A1 publication Critical patent/AR092385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP130103082A 2012-08-31 2013-08-29 FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA AR092385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제

Publications (1)

Publication Number Publication Date
AR092385A1 true AR092385A1 (es) 2015-04-22

Family

ID=50183919

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103082A AR092385A1 (es) 2012-08-31 2013-08-29 FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA

Country Status (28)

Country Link
US (1) US20150231085A1 (enExample)
EP (1) EP2890371A4 (enExample)
JP (1) JP2015526509A (enExample)
KR (1) KR20140030505A (enExample)
CN (1) CN104602678A (enExample)
AR (1) AR092385A1 (enExample)
AU (1) AU2013309688A1 (enExample)
BR (1) BR112015004091A2 (enExample)
CA (1) CA2882738A1 (enExample)
CL (1) CL2015000363A1 (enExample)
CO (1) CO7350622A2 (enExample)
CR (1) CR20150124A (enExample)
DO (1) DOP2015000042A (enExample)
EA (1) EA201590474A1 (enExample)
EC (1) ECSP15010617A (enExample)
IL (1) IL237425A0 (enExample)
IN (1) IN2015DN01738A (enExample)
MA (1) MA37953A1 (enExample)
MX (1) MX2015002591A (enExample)
NI (1) NI201500028A (enExample)
PE (1) PE20150402A1 (enExample)
PH (1) PH12015500395A1 (enExample)
RU (1) RU2015111523A (enExample)
SG (1) SG11201500580QA (enExample)
TW (1) TW201414511A (enExample)
UY (1) UY35000A (enExample)
WO (1) WO2014035190A1 (enExample)
ZA (1) ZA201502157B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
EP3184103A1 (en) * 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
BR112019028235B1 (pt) * 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
WO2009118359A2 (en) * 2008-03-28 2009-10-01 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
WO2009134076A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 방출성이 제어된 안지오텐신 - II - 수용체 차단제와 H M G - C o A 환원 효소 억제제의 복합제 조성물
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome

Also Published As

Publication number Publication date
BR112015004091A2 (pt) 2017-07-04
DOP2015000042A (es) 2015-04-30
RU2015111523A (ru) 2016-10-20
MA37953A1 (fr) 2017-01-31
ECSP15010617A (es) 2015-12-31
MX2015002591A (es) 2015-06-10
KR20140030505A (ko) 2014-03-12
AU2013309688A1 (en) 2015-02-26
US20150231085A1 (en) 2015-08-20
SG11201500580QA (en) 2015-02-27
NI201500028A (es) 2017-01-04
IL237425A0 (en) 2015-04-30
UY35000A (es) 2014-03-31
PH12015500395A1 (en) 2015-04-27
EP2890371A4 (en) 2016-04-06
JP2015526509A (ja) 2015-09-10
CL2015000363A1 (es) 2015-06-05
TW201414511A (zh) 2014-04-16
PE20150402A1 (es) 2015-04-13
EP2890371A1 (en) 2015-07-08
CA2882738A1 (en) 2014-03-06
EA201590474A1 (ru) 2015-06-30
IN2015DN01738A (enExample) 2015-05-29
CO7350622A2 (es) 2015-08-10
CR20150124A (es) 2015-04-24
WO2014035190A1 (en) 2014-03-06
ZA201502157B (en) 2016-10-26
CN104602678A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
AR092385A1 (es) FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA
MX2020010607A (es) Compuestos y metodos para inhibir el transporte de fosfato.
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CR20120545A (es) Formulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX2022015606A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
IN2014DN07410A (enExample)
NI201500027A (es) Formulación de comprimidos compuestos de dos fases que comprenden atorvastatina, irbesartan y carbonato de magnesio.
AR090865A1 (es) Forma farmaceutica oral para la prevencion de enfermedades vasculares, comprimido como forma farmaceutica y capsula de gelatina como forma farmaceutica
MX2016006742A (es) Composicion farmaceutica.
AR100153A1 (es) Medicamento
PT3202772T (pt) Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
ES1187310Y (es) Nevera portatil para medicamentos y productos farmaceuticos
UA100326U (ru) Применение натриевой соли гидрогенсульфида для потенцирования анальгетического эффекта нестероидных противовоспалительных препаратов
TH1501001042A (th) สูตรผสมแคปซูลประกอบแต่งทางเภสัชกรรมที่ประกอบรวมด้วยเออร์เบซาร์แทน และตัวยับยั้ง hmg-coa รีดัคเทส
TH157686A (th) ตัวยับยั้ง cdc7

Legal Events

Date Code Title Description
FB Suspension of granting procedure